The most recent approval of an assay for testing of HER2 amplification was in 2017, when the next generation sequencing assay FoundationOne CDxTM (Foundation Medicine) was approved by the FDA as a companion diagnostic for trastuzumab, pertuzumab, and ado-trastuzumab emtansine in breast cancer (57). The gene discussed is ERBB2; the disease is breast cancer.